VEGF-话题@MedSci

#VEGF#

104篇内容 | 3094人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1368499, encodeId=5b2b13684999e, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=曲安奈德联合抗VEGF药物球内注射治疗脉络膜结核瘤1例, objectType=article, longId=135676, objectId=f12e1356e6fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f12e1356e6fa, replyNumber=0, likeNumber=65, createdTime=2018-04-19, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f12e1356e6fa, moduleTitle=曲安奈德联合抗VEGF药物球内注射治疗脉络膜结核瘤1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f12e1356e6fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368498, encodeId=773d1368498fd, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Biochem Biophys Res Commun：白介素-26通过抑制NFATc1-VEGF途径抑制血管生成, objectType=article, longId=135577, objectId=53e21355e769, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53e21355e769, replyNumber=0, likeNumber=84, createdTime=2018-04-18, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53e21355e769, moduleTitle=Biochem Biophys Res Commun：白介素-26通过抑制NFATc1-VEGF途径抑制血管生成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53e21355e769)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368497, encodeId=0e52136849eff, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Front Pharmacol：Kinsenoside通过Erk / p38 / NF-κB/ VEGF信号改善氧化应激诱导的RPE细胞凋亡并抑制血管发生, objectType=article, longId=135575, objectId=08e81355e529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08e81355e529, replyNumber=0, likeNumber=34, createdTime=2018-04-18, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08e81355e529, moduleTitle=Front Pharmacol：Kinsenoside通过Erk / p38 / NF-κB/ VEGF信号改善氧化应激诱导的RPE细胞凋亡并抑制血管发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08e81355e529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368496, encodeId=c4721368496f7, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Science Translational Medicine：肥胖通过上调IL-6和FGF-2促进乳腺癌对抗-VEGF治疗产生耐药性, objectType=article, longId=133043, objectId=357113304355, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=357113304355, replyNumber=0, likeNumber=84, createdTime=2018-03-23, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=357113304355, moduleTitle=Science Translational Medicine：肥胖通过上调IL-6和FGF-2促进乳腺癌对抗-VEGF治疗产生耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=357113304355)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368495, encodeId=27411368495b6, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Hypertension：Toll样受体9（TLR9)可通过差异性调控VEGFA和sFLT1的表达抑制子娴前期患者母胎界面的血管生成, objectType=article, longId=129138, objectId=dbb8129138b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbb8129138b8, replyNumber=0, likeNumber=73, createdTime=2018-02-08, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbb8129138b8, moduleTitle=Hypertension：Toll样受体9（TLR9)可通过差异性调控VEGFA和sFLT1的表达抑制子娴前期患者母胎界面的血管生成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbb8129138b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368494, encodeId=be9d1368494a6, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Hypertension：Pazopanib，VEGF受体抑制剂，治疗肾细胞癌患者时诱导高血压发生发展的潜在机制。, objectType=article, longId=126213, objectId=393c126213a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=393c126213a4, replyNumber=0, likeNumber=31, createdTime=2018-01-12, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=393c126213a4, moduleTitle=Hypertension：Pazopanib，VEGF受体抑制剂，治疗肾细胞癌患者时诱导高血压发生发展的潜在机制。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=393c126213a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368493, encodeId=862a1368493e6, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Sci Rep：玻璃体内注射抗VEGF药物和预防眼内炎的抗生素：系统分析研究, objectType=article, longId=125217, objectId=97ef12521e5e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97ef12521e5e, replyNumber=0, likeNumber=99, createdTime=2018-01-02, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97ef12521e5e, moduleTitle=Sci Rep：玻璃体内注射抗VEGF药物和预防眼内炎的抗生素：系统分析研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97ef12521e5e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368492, encodeId=98c2136849249, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药, objectType=article, longId=121469, objectId=2c331214690e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c331214690e, replyNumber=0, likeNumber=67, createdTime=2017-11-28, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c331214690e, moduleTitle=CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c331214690e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368491, encodeId=85d3136849183, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=J Clin Periodontol：成纤维细胞VEGF受体1或是牙周炎新的治疗靶点, objectType=article, longId=118890, objectId=61b3118890c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61b3118890c0, replyNumber=0, likeNumber=71, createdTime=2017-11-07, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61b3118890c0, moduleTitle=J Clin Periodontol：成纤维细胞VEGF受体1或是牙周炎新的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61b3118890c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368490, encodeId=e5e51368490a3, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Nat Commun：VEGF-MPs可提高血管生成细胞治疗缺血性疾病的效果, objectType=article, longId=115440, objectId=6307115440e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6307115440e5, replyNumber=0, likeNumber=78, createdTime=2017-10-10, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6307115440e5, moduleTitle=Nat Commun：VEGF-MPs可提高血管生成细胞治疗缺血性疾病的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6307115440e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368489, encodeId=202913684895b, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Diabetologia：VEGF-A抑制剂sFLT-1通过减少1型糖尿病小鼠模型中的内皮活化和炎症来改善肾功能, objectType=article, longId=115003, objectId=9bd41150035d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bd41150035d, replyNumber=0, likeNumber=74, createdTime=2017-10-02, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bd41150035d, moduleTitle=Diabetologia：VEGF-A抑制剂sFLT-1通过减少1型糖尿病小鼠模型中的内皮活化和炎症来改善肾功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bd41150035d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368488, encodeId=ed0a13684889c, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药, objectType=article, longId=113909, objectId=a3b411390971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3b411390971, replyNumber=0, likeNumber=53, createdTime=2017-09-25, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3b411390971, moduleTitle=CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3b411390971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368487, encodeId=4755136848ea1, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=诺华制药：抗VEGF药物疗效比较，头对头数据来验证, objectType=article, longId=112814, objectId=053511281469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053511281469, replyNumber=0, likeNumber=74, createdTime=2017-09-16, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053511281469, moduleTitle=诺华制药：抗VEGF药物疗效比较，头对头数据来验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=053511281469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368486, encodeId=5b8c1368486ff, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关, objectType=article, longId=112313, objectId=3530112313d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3530112313d7, replyNumber=0, likeNumber=69, createdTime=2017-09-09, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3530112313d7, moduleTitle=Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3530112313d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368485, encodeId=35d3136848542, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Invest Ophthalmol Vis Sci：Fc区域对抗VEGF药物在玻璃体半衰期中的作用！, objectType=article, longId=111559, objectId=8839111559a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8839111559a0, replyNumber=0, likeNumber=62, createdTime=2017-09-02, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8839111559a0, moduleTitle=Invest Ophthalmol Vis Sci：Fc区域对抗VEGF药物在玻璃体半衰期中的作用！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8839111559a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368484, encodeId=b43613684841a, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110822, objectId=f90d11082200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f90d11082200, replyNumber=0, likeNumber=72, createdTime=2017-08-26, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f90d11082200, moduleTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f90d11082200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368483, encodeId=8d8613684838d, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110820, objectId=ca66110820db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca66110820db, replyNumber=0, likeNumber=61, createdTime=2017-08-26, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca66110820db, moduleTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca66110820db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368482, encodeId=9488136848295, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Lancet Oncol：晚期肾癌VEGF靶向治疗进展后， cabozantinib成新标准？, objectType=article, longId=108931, objectId=e67710893136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e67710893136, replyNumber=0, likeNumber=0, createdTime=2017-08-17, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e67710893136, moduleTitle=Lancet Oncol：晚期肾癌VEGF靶向治疗进展后， cabozantinib成新标准？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e67710893136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368481, encodeId=56ee136848115, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Hypertension：VEGF受体酪氨酸激酶抑制剂是否影响长期肾功能呢？, objectType=article, longId=107840, objectId=4e2510e840de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2510e840de, replyNumber=0, likeNumber=79, createdTime=2017-08-07, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2510e840de, moduleTitle=Hypertension：VEGF受体酪氨酸激酶抑制剂是否影响长期肾功能呢？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2510e840de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368480, encodeId=8ebe13684800d, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, objectTitle=Int Endod J：VEGF通过调节赖氨酰氧化酶的表达诱导人牙髓细胞的分化和血管发生, objectType=article, longId=102862, objectId=1757102862c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1757102862c8, replyNumber=0, likeNumber=65, createdTime=2017-06-23, rootId=0, userName=fanweitanzhen, userId=80ca273, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1757102862c8, moduleTitle=Int Endod J：VEGF通过调节赖氨酰氧化酶的表达诱导人牙髓细胞的分化和血管发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1757102862c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

VEGF

2020-05-29

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

曲安奈德联合抗VEGF药物球内注射治疗脉络膜结核瘤1例

2018-04-19

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Biochem Biophys Res Commun：白介素-26通过抑制NFATc1-VEGF途径抑制血管生成

2018-04-18

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Front Pharmacol：Kinsenoside通过Erk / p38 / NF-κB/ VEGF信号改善氧化应激诱导的RPE细胞凋亡并抑制血管发生

2018-04-18

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Science Translational Medicine：肥胖通过上调IL-6和FGF-2促进乳腺癌对抗-VEGF治疗产生耐药性

2018-03-23

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Hypertension：Toll样受体9（TLR9)可通过差异性调控VEGFA和sFLT1的表达抑制子娴前期患者母胎界面的血管生成

2018-02-08

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Hypertension：Pazopanib，VEGF受体抑制剂，治疗肾细胞癌患者时诱导高血压发生发展的潜在机制。

2018-01-12

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Sci Rep：玻璃体内注射抗VEGF药物和预防眼内炎的抗生素：系统分析研究

2018-01-02

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

CLIN CANCER RES：巨噬细胞通过改变VEGFR表达促进抗VEGF治疗耐药

2017-11-28

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

J Clin Periodontol：成纤维细胞VEGF受体1或是牙周炎新的治疗靶点

2017-11-07

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Nat Commun：VEGF-MPs可提高血管生成细胞治疗缺血性疾病的效果

2017-10-10

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Diabetologia：VEGF-A抑制剂sFLT-1通过减少1型糖尿病小鼠模型中的内皮活化和炎症来改善肾功能

2017-10-02

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药

2017-09-25

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

诺华制药：抗VEGF药物疗效比较，头对头数据来验证

2017-09-16

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关

2017-09-09

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Invest Ophthalmol Vis Sci：Fc区域对抗VEGF药物在玻璃体半衰期中的作用！

2017-09-02

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Lancet Oncol：晚期肾癌VEGF靶向治疗进展后， cabozantinib成新标准？

2017-08-17

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Hypertension：VEGF受体酪氨酸激酶抑制剂是否影响长期肾功能呢？

2017-08-07

fanweitanzhen (审核中...)

前往app查看评论内容

#VEGF#

Int Endod J：VEGF通过调节赖氨酰氧化酶的表达诱导人牙髓细胞的分化和血管发生

2017-06-23

科室
- - 订阅+
  - 更多科室
工具
服务